Some features of oral mucosal disease symptoms and clinical manifestations in patients with chronic inflammatory bowel disease

Relevance. The work presents the results of a comprehensive dental examination of patients with vermilion and oral mucosa proper (OM) diseases associated with manifestations of Crohn's disease (CD) and ulcerative colitis (UC).

Aim. To determine the cause-related features of complaints and clinical manifestations of vermilion and OM diseases.

Material and methods. The comprehensive dental examination included the analysis of complaints, history, and assessment of the vermilion and OM condition and the nociceptive pain severity score according to the Visual Analog Scale (VAS).

Results and discussion. In CD and UC, the vermillion diseases clinically manifested in 51.43% and 42.85% of subjects (p < 0.01), OM chronic trauma – in 40.0% and 31.43% (p < 0.05), chronic recurrent aphthae – in 48.47% (p < 0.001) and 31.43% (p < 0.01), glossitis – in 62.86% (p < 0.001) and 25.71% (p < 0.01), glossodynia – in 31.43% (p < 0.01) and 17.15% (p < 0.05) of cases. The main complaints of patients with the detected OM pathology included unpleasant sensations, like rawness and soreness, on taking irritating foods in 100% and 65.71% and talking in 31.43% and 25.71% of cases, dry mouth in 51.43% and 25.71% of cases. The burning mouth syndrome was in 31.43% and 17.15% of patients.

Conclusion. The vermilion and the oral mucosal diseases often prevail associated with the clinical course of Crohn'sdisease compared to patients with UC. The VAS pain severity score hinges on CD and UC course (p < 0.055). The variety of clinical manifestations of the vermillion and oral mucosal diseases directly depends on CD and UC, a criterion for developing an integrated approach to their diagnosis and implementing recommendations for their prevention and treatment in practical health care.

1. Robakidze NS, Baranovsky AY. The analysis of recurrent aphthous stomatitis of the patients with inflammatory bowel disease. The Dental Institute. 2016;1(70):58-59 (In Russ.). Available from: elibrary.ru/item.asp?id=25844124

2. Bakulin IG, Zhigalova TN, Latariya EL, Skazyvaeva EV, Skalinskaya MI, Sitkin SI, et al. Experience of introduction of the Federal Registry of patients with inflammatory bowel diseases in Saint Petersburg. Farmateka. 2017;5:56−59 (In Russ.). Available from: elibrary.ru/item.asp?id=30754549

3. Bakulin IG, Skalinskaya MI, Skazyvaeva EV. NorthWestern register of patients with inflammatory bowel diseases: achievements and lessons learned. Koloproktologia. 2022;21(1):37-49 (In Russ). doi: 10.33878/2073-7556-2022-21-1-37-49

4. Binnatli ShA, Aleshin DV, Kulikov AE, Romanov RI. Quality life of patients operated for ulcerative colitis. Koloproktologia. 2019;18(1):89−100 (In Russ.). doi: 10.33878/2073-7556-2019-18-1-89-100

5. Kliaritskaia IL, Stilidi EI, Maksimova EV, Shakhbazidi G. Extraintestinal manifestations of inflammatory bowel disease. Crimean journal of internal diseases. 2017;32(1):47-51 (In Russ.). Available from: elibrary.ru/item.asp?id=28367558

6. Gaus OV, Akhmedov VA, Korshunov AS. Aphthous stomatitis as the debut of Crohn’s disease. Experimental and Clinical Gastroenterology. 2019;9:97-100 (In Russ.). doi: 10.31146/1682-8658-ecg-169-9-97-100

7. Kagramanova AV, Mikhailova SF, Knyazev OV, Fadeeva NA, Lishchinskaya AA, Parfenov AI. Extraintestinal manifestations of inflammatory bowel diseases. Therapy. 2017;4(14):107–118 (In Russ.). Available from: https://journals.eco-vector.com/2412-4036/article/view/277699

8. Kolomiets SV, Udaltsova KA, Shinkevich VI. Manifestation of Crohn’s disease in the oral cavity: clinical case. Stomatologiya. 2017;96(5):28-30 (In Russ.). doi: 10.17116/stomat201796528-30

9. Maev IV, Shelygin YA, Skalinskaya MI, Veselov AV, Skazyvaeva EV, Rasmagina IA, et al. The Pathomorphosis of Inflammatory Bowel Diseases. Annals of the Russian Academy of Medical Sciences. 2020;75(1):27–35 (In Russ.). doi: 10.15690/vramn1219

10. International Classification of Orofacial Pain, 1st edition (ICOP). Adapted Russian-language version. Almanac of Clinical Medicine. 2022;50:1-82. doi: 10.18786/2072-0505-2022-50-005

11. Osipenko MF, Valuiskikh EYu, Svetlova IO, Kulygina YuA, Skalinskaya MI, Bikbulatova EA, et al. Register of inflammatory bowel diseases in Novosibirsk-2016. The Siberian scientific medical journal. 2017;37(1):61−67 (In Russ.). Available from: elibrary.ru/item.asp?id=28280117

12. Robakidze NS, Shchukina OB. Pathogenetic Aspects of Oral Cavity Lesions in Inflammatory Gastrointestinal Tract Diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(4):15-21 (In Russ.). doi: 10.22416/1382-4376-2019-29-4-15-21

13. Shipitsyna MS, Tytyuk SYu, Iordanishvili AK. Dental morbidity in crohn's disease and chronic ulcerative colitis. Medicine: theory and practice. 2018;3(1):121 (In Russ.). Available from: https://cyberleninka.ru/article/n/stomatologicheskaya-zabolevaemost-pri-bolezni-krona-i-hronicheskom-nespetsificheskom-yazvennom-kolite

14. Trukhan LYu, Trukhan DI. Stomatoligical problems of gastroenterological patients and their possible solutions. Medical Council. 2016;(19):134-137 (In Russ.). doi: 10.21518/2079-701X-2016-19-134-137

15. Shelygin YuA, Veselov AV, Serbina AA. Main directions of organization of a specialized coloproctological medical care. Koloproktologia. 2017;(1):76−81 (In Russ.). doi: 10.33878/2073-7556-2017-0-1-76-81

16. Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, et al. Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Alimentary pharmacology & therapeutics. 2016;44(6):554–567. doi: 10.1111/apt.13736

17. Bernstein CN, Benchimol EI, Bitton A, Murthy SK, Nguyen GC, Lee K, et al. The impact of inflammatory bowel disease in Canada 2018: extra-intestinal diseases in IBD. J Canad Ass Gastr. 2019;2(1):73–80. doi: 10.1093/jcag/gwy053

18. Bernstein CN. Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology. Alimentary pharmacology & therapeutics. 2017;46(10):911−919. doi.org/10.1111/apt.14338

19. Ghersin I, Khteeb N, Katz LH, Daher S, Shamir R, Assa A. Trends in the epidemiology of inflammatory bowel disease among jewish Israeli adolescents: a population-based study. Alimentary pharmacology & therapeutics. 2019;49(5):556−563. doi: 10.1111/apt.15160

20. Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The First European Evidence-based Consensus on Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's & colitis. 2016;10(3):239–254. doi:10.1093/ecco-jcc/jjv213

21. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Eric MPhil, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2018;390(10114):2769−2778. doi: 10.1016/S0140-6736(17)32448-0

22. Park SH, Kim YJ, Rhee KH, Kim YH, Hong SN, Kim KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the SongpaKangdong district of Seoul, Korea in 1986−2015. Journal of Crohn's & colitis. 2019;13(11):1410−1417. doi: 10.1093/ecco-jcc/jjz081

23. Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Current gastroenterology reports. 2019;21(8):40−46. doi:10.1007/s11894-019-0705-6